hronic lymphocytic leukemia
Dec 12, 2023
Liso-cel in TRANSCEND CLL 004: Unprecedented and Sustained Responses with Manageable Safety Profile, Signaling a Promising Advance in Relapsed or Refractory CLL Treatment
Date of Abstract presentation9th December 2023IndicationsChronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)Abstract Number330Abstract typeOral TRANSCEND CLL 004 is the first pivotal, multicenter study of a CD19-directed CAR T cell therapy for patients with relapsed or refractory chronic lymp...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
